Aptevo Therapeutics Announces Promising RAINIER Trial Results

Aptevo Therapeutics ( (APVO) ) just unveiled an announcement.

On December 9, 2025, Aptevo Therapeutics announced promising results from its Phase 1b/2 RAINIER trial for mipletamig in combination with azacitidine and venetoclax for newly diagnosed AML patients unfit for intensive chemotherapy. The trial demonstrated high remission rates and a compelling safety profile, with 100% of patients remaining free of cytokine release syndrome. The results underscore mipletamig’s potential as part of a frontline AML regimen, with the study continuing to enroll patients for further evaluation.

The most recent analyst rating on (APVO) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Aptevo Therapeutics stock, see the APVO Stock Forecast page.

Spark’s Take on APVO Stock

According to Spark, TipRanks’ AI Analyst, APVO is a Underperform.

Aptevo Therapeutics’ stock score is significantly impacted by its challenging financial performance, marked by declining revenues, high leverage, and negative cash flows. The technical analysis indicates bearish momentum, while the valuation is weakened by persistent losses. However, promising developments in its oncology pipeline offer potential upside if successfully executed.

To see Spark’s full report on APVO stock, click here.

More about Aptevo Therapeutics

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific and trispecific immunotherapies for cancer treatment. The company utilizes its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies to create therapeutic candidates, including mipletamig for acute myeloid leukemia (AML) and ALG.APV-527 for multiple solid tumors.

Average Trading Volume: 5,927,335

Technical Sentiment Signal: Strong Sell

Current Market Cap: $22.75M

See more insights into APVO stock on TipRanks’ Stock Analysis page.